NCT00310180 2026-04-13
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT01272037 2026-04-13
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02311933 2026-04-13
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT02747004 2026-02-06
Next MONARCH 1
Eli Lilly and Company
Phase 2 Active not recruiting
NCT03879577 2026-01-21
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
University of Chicago
Phase 2 Active not recruiting
NCT01196936 2026-01-05
LDTam
University of Alabama at Birmingham
Phase 2 Active not recruiting
NCT04272801 2025-10-22
POWER
University of Virginia
Phase 2 Active not recruiting
NCT02764541 2025-05-07
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting